Saturday 17 October 2026
Export EIGRQ’s income statement to Excel — free account
Eiger BioPharmaceuticals, Inc.
EIGRQ Healthcare Biotechnology
Eiger BioPharmaceuticals, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $15.8 million, up 17.0% from fiscal 2022. Revenue growth for three consecutive years, operating cash flow growth for three.
8.50
0.00
0.00%
Follow EIGRQ
Eiger BioPharmaceuticals, Inc. (EIGRQ) P/E ratio
Eiger BioPharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2024) to 0.0× (October 2024) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| 8 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SLXN Silexion Therapeutics Corp compare | n/m |
| XRTX XORTX Therapeutics Inc. compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | n/m |
| VBIO Valion Bio, Inc. compare | n/m |
| GOVX GeoVax Labs Inc. compare | n/m |
| NTBLQ Notable Labs, Ltd. compare | n/m |
| ELAB PMGC Holdings Inc. compare | n/m |
| EIGRQ Eiger BioPharmaceuticals, Inc. | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)